<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00881101</url>
  </required_header>
  <id_info>
    <org_study_id>LPS- PH I -01-2009</org_study_id>
    <nct_id>NCT00881101</nct_id>
  </id_info>
  <brief_title>Clinical Study of Liposomal Paclitaxel in Chinese Patients</brief_title>
  <official_title>Dose Escalation Study of Liposomal Paclitaxel in Chinese Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing Sike Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing Sike Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the maximum tolerated dose and dose limiting
      toxicities of liposomal paclitaxel in Chinese patients with solid tumors in advanced stages.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are clinical trials show that paclitaxel is common option for the treatment of solid
      tumors. Liposomal paclitaxel has different pharmacokinetic features comparing with
      conventional paclitaxel. However,the tolerance of this new dosage form of paclitaxel
      (liposomal paclitaxel) has never been studied in Chinese cancer patients. This study is
      designed to find the maximum tolerated dose and dose limiting toxicities of liposomal
      paclitaxel in Chinese cancer patients.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2009</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">October 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>maximum tolerated dose</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>dose limiting toxicity</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liposomal paclitaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal paclitaxel</intervention_name>
    <description>All Patients will receive liposomal paclitaxel (starting at a dose of 190mg/m2,3h,ivgtt,at d1)each cycle for 1 cycle.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age: from 18 to 70

          2. Patients with solid tuomors at advanced stage must be histologically or cytologically
             confirmed ,and be suitable for treating with Paclitaxel Liposome solo

          3. Eastern Cooperative Oncology Group (ECOG) performance status (PS)is from 0 to 2

          4. Patients who are expected to live at least 3 months

          5. Laboratory tests before the study: white blood count (WBC)≥4,000/mm³,absolute
             neutrophil count (ANC) ≥1,500/mm³, platelet count ≥100,000/mm³, hemoglobin≥9.0 g/dL,
             aspartate aminotransferase AST (sGOT) and alanine aminotransferase ALT(sGPT)≤2.5 times
             of normal value upper limit，serum creatinine≤1.0 time of normal value upper
             limit，total bilirubin≤1.5 times of normal value upper limit

          6. Not using chemotherapeutics (including test drug)before the study trial at least 4
             weeks

          7. No obvious functional disturbance diseases of internal organs

          8. Complying with the study protocol

          9. Sign informed consent

         10. No Previous anaphylactic reaction to hormone

        Exclusion Criteria:

          1. Allergy to any medication or foods; History of hypersensitivity reactions to the
             conventional dosage form of paclitaxel or correlate excipients

          2. Active uncontrolled central nervous system metastasis

          3. Severe complications that obviously influence the compliance of patients

          4. Grade ≥1 neuropathy using NCI CTCAE version 3.0 criteria

          5. Taking other study medications or participating other clinical trial within 4w

          6. Having radiation therapy or operation within 4w

          7. Any non-remission toxicity ≥ CTC 1 in prior anticancer therapy(including radiation
             therapy) (except alopecie and hemoglobin)

          8. Pregnant or lactant women; fertile patients not using effective contraception during
             study

          9. No chief organ functional disturbance or diseases:

               -  abnormal liver and renal functions

               -  myocardial infarction

               -  active heart disease

               -  neuropathy or mental diseases including dementia or epilepsy

               -  blind、deaf、dumb or extremity disability

               -  known infection

               -  active diffuse intravascular coagulation

         10. Others whom researchers regard not eligible for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin Li, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Hospital of Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The ethics committee of Cancer Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2009</study_first_submitted>
  <study_first_submitted_qc>April 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2009</study_first_posted>
  <last_update_submitted>April 14, 2009</last_update_submitted>
  <last_update_submitted_qc>April 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2009</last_update_posted>
  <responsible_party>
    <name_title>Jin Li, Dr.</name_title>
    <organization>Cancer Hospital of Fudan University</organization>
  </responsible_party>
  <keyword>Liposomal Paclitaxel</keyword>
  <keyword>Maximum tolerated dose</keyword>
  <keyword>Dose limiting toxicity</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

